Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Reap EA, Morris J, Dryga SA, Maughan M, Talarico T, Esch RE, Negri S, Burnett B, Graham A, Olmsted RA, Chulay JD.

Vaccine. 2007 Oct 16;25(42):7441-9. Epub 2007 Aug 30.

2.

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI, Copp L, Lewis W, Cecil C, Norberg P, Wagner J, Watson A, Negri S, Burnett BK, Graham A, Smith JF, Chulay JD.

Vaccine. 2007 Nov 23;25(48):8180-9. Epub 2007 Oct 5.

3.

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Reap EA, Dryga SA, Morris J, Rivers B, Norberg PK, Olmsted RA, Chulay JD.

Clin Vaccine Immunol. 2007 Jun;14(6):748-55. Epub 2007 Apr 18.

4.

The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.

Lilja AE, Mason PW.

Vaccine. 2012 Nov 19;30(49):6980-90. doi: 10.1016/j.vaccine.2012.09.056. Epub 2012 Oct 3. Review.

PMID:
23041121
5.

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD.

Vaccine. 2009 Dec 11;28(2):484-93. doi: 10.1016/j.vaccine.2009.09.135. Epub 2009 Oct 24.

PMID:
19857446
6.

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.

Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA, Palladino G, Franti M, Mandl CW, Barnett SW, Mason PW.

Vaccine. 2013 Jan 30;31(6):919-26. doi: 10.1016/j.vaccine.2012.12.009. Epub 2012 Dec 14.

PMID:
23246547
7.

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.

Wang Z, La Rosa C, Lacey SF, Maas R, Mekhoubad S, Britt WJ, Diamond DJ.

J Clin Virol. 2006 Mar;35(3):324-31. Epub 2006 Jan 4.

PMID:
16388983
8.

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection.

Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD, Smith JF.

J Infect Dis. 2007 Mar 15;195(6):789-98. Epub 2007 Feb 6.

PMID:
17299708
9.

Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.

Kirchmeier M, Fluckiger AC, Soare C, Bozic J, Ontsouka B, Ahmed T, Diress A, Pereira L, Schödel F, Plotkin S, Dalba C, Klatzmann D, Anderson DE.

Clin Vaccine Immunol. 2014 Feb;21(2):174-80. doi: 10.1128/CVI.00662-13. Epub 2013 Dec 11.

10.

A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge.

Greer CE, Zhou F, Legg HS, Tang Z, Perri S, Sloan BA, Megede JZ, Uematsu Y, Vajdy M, Polo JM.

Vaccine. 2007 Jan 5;25(3):481-9. Epub 2006 Aug 7.

PMID:
17052811
11.

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.

Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S, Daftarian P, Longmate J, Britt WJ, Diamond DJ.

J Virol. 2004 Apr;78(8):3965-76.

12.

A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

McVoy MA, Lee R, Saccoccio FM, Hartikka J, Smith LR, Mahajan R, Wang JB, Cui X, Adler SP.

Vaccine. 2015 Dec 16;33(51):7328-36. doi: 10.1016/j.vaccine.2015.10.078. Epub 2015 Oct 24.

13.

An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.

White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, Johnston RE.

J Virol. 2007 Oct;81(19):10329-39. Epub 2007 Jul 25.

14.

A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever.

Sun Y, Li HY, Tian DY, Han QY, Zhang X, Li N, Qiu HJ.

Vaccine. 2011 Oct 26;29(46):8364-72. doi: 10.1016/j.vaccine.2011.08.085. Epub 2011 Sep 5.

PMID:
21888938
15.

Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.

Schleiss MR, Bourne N, Jensen NJ, Bravo F, Bernstein DI.

Viral Immunol. 2000;13(2):155-67.

PMID:
10892996
16.

Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.

Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.

Vaccine. 2006 Apr 5;24(15):2755-63. Epub 2006 Jan 19.

PMID:
16460840
17.

A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.

Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC.

Clin Cancer Res. 2007 Jul 1;13(13):3999-4008.

18.

Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Uematsu Y, Vajdy M, Lian Y, Perri S, Greer CE, Legg HS, Galli G, Saletti G, Otten GR, Rappuoli R, Barnett SW, Polo JM.

Clin Vaccine Immunol. 2012 Jul;19(7):991-8. doi: 10.1128/CVI.00031-12. Epub 2012 May 23.

19.

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.

Mersseman V, Böhm V, Holtappels R, Deegen P, Wolfrum U, Plachter B, Reyda S.

Med Microbiol Immunol. 2008 Jun;197(2):97-107. doi: 10.1007/s00430-008-0085-2. Epub 2008 Mar 5.

PMID:
18320219
20.

Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.

Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN, Wolchok JD.

PLoS One. 2010 Sep 10;5(9). pii: e12670. doi: 10.1371/journal.pone.0012670.

Supplemental Content

Support Center